RT Journal Article SR Electronic T1 Clinical Significance of TAP1 and DLL4 Expression in Patients With Locally Advanced Gastric Cancer JF In Vivo JO In Vivo FD International Institute of Anticancer Research SP 2771 OP 2777 DO 10.21873/invivo.12562 VO 35 IS 5 A1 KENKI SEGAMI A1 TORU AOYAMA A1 YUKIHIKO HIROSHIMA A1 KEISUKE KOMORI A1 ITARU HASHIMOTO A1 HAYATO WATANABE A1 KAZUKI KANO A1 SHINSUKE NAGASAWA A1 MASATO NAKAZONO A1 YUKIO MAEZAWA A1 HIROHITO FUJIKAWA A1 MASAKATSU NUMATA A1 TAKANOBU YAMADA A1 HIROSHI TAMAGAWA A1 NAOTO YAMAMOTO A1 TAKASHI OGATA A1 MANABU SIOZAWA A1 NORIO YUKAWA A1 SOICHIRO MORINAGA A1 YASUSHI RINO A1 MUNETAKA MASUDA A1 YOHEI MIYAGI A1 HIROSHI SAEKI A1 TAKASHI OSHIMA YR 2021 UL http://iv.iiarjournals.org/content/35/5/2771.abstract AB Background/Aim: Cancer stem cells (CSCs) are reported to associated with cancer metastasis, relapse, and chemoresistance. This study examined the clinical significance of the expression of two CSC markers, the transporter associated with antigen processing 1 (TAP1) and the Delta-like 4 (DLL4) protein, in patients with locally advanced GC. Patients and Methods: This study was performed using samples obtained from 413 pathological stage II/III GC patients after curative gastrectomy. We examined TAP1 and DLL4 expression using immunohistochemical analysis with tissue microarray and examined the association between TAP1 or DLL4 expression, clinicopathological factors and survival. Results: High TAP1 expression was associated with better overall survival compared to low TAP1 expression (p=0.004). Furthermore, in multivariate analysis, high TAP1 expression was defined as a predictive factor for good survival. There was no significant difference between DLL4 expression and clinicopathological features and overall survival. Conclusion: TAP1 expression may be a useful prognostic marker in patients with locally advanced GC.